Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
DMX-200's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for DMX-200. Showing past 6 months and next 12 months · 11 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| DMX-200 | Dimerix | Gpcr Modulator | Phase 2 | 0 | ||||
| Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy | Calliditas Therapeutics AB | Gpcr Modulator |
Read-across commentary attached per trial. Phase ordering preserved within each group.
| Mechanism | Speed to patient | Manufacturing | Best approved result | Durability | Moat |
|---|---|---|---|---|---|
| Fc Fusion ProteinFc-fusion trap | Off-the-shelf | Biologic | Eylea / Vabysmo class | Dosing-interval driven | High (incumbents) |
| Antisense oligonucleotideASO | Off-the-shelf | Synthetic | Approved (SMA/DMD) | Chronic dosing | Moderate |
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. | Fondazione Schena | Other | Phase 4 | — | — | — | — | — |
| Nefecon and Ambrisentan in IgA Nephropathy | The First Hospital of Jilin University | Gpcr Modulator | Phase 4 | — | — | — | — | — |
| Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis | Travere Therapeutics, Inc. | Gpcr Modulator | Phase 4 | — | — | — | — | — |
| Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy: a Randomized, Double-blinded, Placebo-Controlled Trial | Nanfang Hospital, Southern Medical University | Small Molecule Other | Phase 4 | — | — | — | — | — |
| Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? | Christian Medical College, Vellore, India | Other | Phase 4 | — | — | — | — | — |
| A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy | Travere Therapeutics, Inc. | Gpcr Modulator | Phase 3 | — | — | — | — | — |
| Atacicept in Subjects With IgA Nephropathy | Vera Therapeutics, Inc. | Fc Fusion Protein | Phase 3 | — | — | — | — | — |
| To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy | The Affiliated Hospital of Xuzhou Medical University | Fc Fusion Protein | Phase 3 | — | — | — | — | — |
| Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD | Air Force Military Medical University, China | Other | Phase 3 | — | — | — | — | — |
| Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) | Alexion Pharmaceuticals, Inc. | Monoclonal antibody | Phase 3 | — | — | — | — | — |
| Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Monoclonal antibody | Phase 3 | — | — | — | — | — |
| A Study of Telitacicept for IgA Nephropathy (TELIGAN) | RemeGen Co., Ltd. | Fc Fusion Protein | Phase 3 | — | — | — | — | — |
| Effect of Finerenone in IgA Nephropathy | Zhejiang University | Small Molecule Other | Phase 3 | — | — | — | — | — |
| A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression | Hoffmann-La Roche | Antisense oligonucleotide | Phase 3 | — | — | — | — | — |
| A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria | Biocity Biopharmaceutics Co., Ltd. | Gpcr Modulator | Phase 3 | — | — | — | — | — |
| A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | Biogen | Monoclonal antibody | Phase 3 | — | — | — | — | — |
| Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis | Guixia Ding | Fc Fusion Protein | Phase 3 | — | — | — | — | — |
| A Study of Zigakibart in Adults With IgA Nephropathy | Novartis Pharmaceuticals | Monoclonal antibody | Phase 3 | — | — | — | — | — |
| A Trial of HRS-5965 Capsule in Primary IgA Nephropathy | Chengdu Suncadia Medicine Co., Ltd. | Gpcr Modulator | Phase 3 | — | — | — | — | — |
| Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN | Haisco Pharmaceutical Group Co., Ltd. | Small Molecule Other | Phase 3 | — | — | — | — | — |
| Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) | Alpine Immune Sciences Inc, A Subsidiary of Vertex | Fc Fusion Protein | Phase 3 | — | — | — | — | — |
| Atrasentan in Patients With IgA Nephropathy | Novartis Pharmaceuticals | Gpcr Modulator | Phase 3 | — | — | — | — | — |
| Study of Ravulizumab in Pediatric Participants With Primary IgAN | Alexion Pharmaceuticals, Inc. | Monoclonal antibody | Phase 3 | — | — | — | — | — |
| A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy | Takeda | Monoclonal antibody | Phase 3 | — | — | — | — | — |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN | Novartis Pharmaceuticals | Small Molecule Other | Phase 3 | — | — | — | — | — |
| A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy | Novartis Pharmaceuticals | Small Molecule Other | Phase 3 | — | — | — | — | — |
| Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. | Novartis Pharmaceuticals | Other | Phase 3 | — | — | — | — | — |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN | Novartis Pharmaceuticals | Gpcr Modulator | Phase 3 | — | — | — | — | — |
| Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Other | PHASE2/PHASE3 | — | — | — | — | — |
| Study of Telitacicept in Patients With Refractory IgA Nephropathy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Fc Fusion Protein | PHASE2/PHASE3 | — | — | — | — | — |
| Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Monoclonal antibody | PHASE2/PHASE3 | — | — | — | — | — |
| Atrasentan in Patients With Proteinuric Glomerular Diseases | Novartis Pharmaceuticals | Gpcr Modulator | Phase 2 | — | — | — | — | — |
| A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease | Biocity Biopharmaceutics Co., Ltd. | Small Molecule Other | Phase 2 | — | — | — | — | — |
| A Trial of HRS-5965 Tablets in Primary IgA Nephropathy | Chengdu Suncadia Medicine Co., Ltd. | Gpcr Modulator | Phase 2 | — | — | — | — | — |
| A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy | University of Leicester | Gpcr Modulator | Phase 2 | — | — | — | — | — |
| Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN | Haisco Pharmaceutical Group Co., Ltd. | Small Molecule Other | Phase 2 | — | — | — | — | — |
| A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy | Hansoh BioMedical R&D Company | Gpcr Modulator | Phase 2 | — | — | — | — | — |
| Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis | Kira Pharmacenticals (US), LLC. | Gpcr Modulator | Phase 2 | — | — | — | — | — |
| Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) | Wuhan Createrna Science and Technology Co., Ltd | Gpcr Modulator | Phase 2 | — | — | — | — | — |
| A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases | Suzhou Sanegene Bio Inc. | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Monthly Dosing of Atacicept in IgAN | Vera Therapeutics, Inc. | Fc Fusion Protein | Phase 2 | — | — | — | — | — |
| Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy | Nanjing Chia-tai Tianqing Pharmaceutical | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Study of CM313 in Subject With IgA Nephropathy | Keymed Biosciences Co.Ltd | Gpcr Modulator | Phase 2 | — | — | — | — | — |
| Study of WAL0921 in Patients With Glomerular Kidney Diseases | Walden Biosciences | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | Travere Therapeutics, Inc. | Gpcr Modulator | Phase 2 | — | — | — | — | — |
| A Study of SHR-2173 in Participants With Primary IgA Nephropathy | Guangdong Hengrui Pharmaceutical Co., Ltd | Gpcr Modulator | Phase 2 | — | — | — | — | — |
| Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy | Keymed Biosciences Co.Ltd | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Atacicept in Multiple Glomerular Diseases | Vera Therapeutics, Inc. | Fc Fusion Protein | Phase 2 | — | — | — | — | — |
| Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN | Novartis Pharmaceuticals | Other | Phase 2 | — | — | — | — | — |